March 22, 2010
Phase 2 study of CCX140 for the treatment of type 2 diabetes mellitus (DM)ChemoCentryx announced that it has undertaken a Phase 2 trial of CCX140 for the treatment of type 2 diabetes mellitus. This randomized, double-blind, placebo- and active-controlled study is expected to enroll approximately 140 patients. Eligible patients will be randomized to one of four treatment groups as follows: placebo once daily; pioglitazone hydrochloride at 30 mg once daily; CCX140 at 5 mg once daily and CCX140 at 10 mg once daily. Dosing will be for 28 days with a 28-day follow-up period. The primary objective of this study is to evaluate the safety and tolerability of CCX140 in subjects with type 2 diabetes based on incidence of adverse events. Secondary endpoints in the study include fasting glucose and insulin concentrations, homeostasis model assessment of insulin resistance (HOMA-IR), glucose control based on HbA1c and serum total adiponectin concentrations.
CCX140 is a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2. This receptor has been shown to play a role in the inflammatory response associated with metabolic diseases including type 2 diabetes, as well as other diseases including vascular restenosis following stent placement, and multiple sclerosis.
For more information call (650) 210-2900 or visit www.chemocentryx.com.